Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612209 | 0.82 | ALDH1A1 (0.38) | CHATALDH1A1CYP2A6CA1CA2 | |
| SCHEMBL6003188 | 0.80 | CHAT (0.39) | CHATALDH1A1CYP2A6CA1CA2 | |
| SCHEMBL1611479 | 0.78 | CHAT (0.40) | CHATALDH1A1CYP2A6CA1CA2 | |
| SCHEMBL6003313 | 0.75 | CA1 (0.40) | CHATALDH1A1CYP2A6CA1CA2 | |
| SCHEMBL50728 | 0.75 | CA1 (0.40) | CHATALDH1A1CYP2A6CA1CA2 | |
| SCHEMBL1610598 | 0.75 | CHAT (0.38) | CHATALDH1A1CYP2A6CA1CA2 | |
| SCHEMBL59702 | 0.75 | CA1 (0.69) | CHATALDH1A1CYP2A6CA1CA2 | |
| SCHEMBL5865111 | 0.75 | CA1 (0.47) | CHATALDH1A1CYP2A6CA1CA2 | |
| SCHEMBL1663806 | 0.75 | ALDH1A1 (0.48) | CHATALDH1A1CYP2A6CA1CA2 | |
| SCHEMBL1141298 | 0.74 | HPRT1 (0.52) | CHATALDH1A1CYP2A6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116535460-A | Sulfur-containing peptidomimetic compounds, and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-08-04 | — | — | CN | claimed |
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | claimed |
| CN-116535460-A | Sulfur-containing peptidomimetic compounds, and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-08-04 | — | — | CN | disclosed |
| US-7943612-B2 | Compounds that modulate PPAR activity, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20110087034-A1 | Organic Semiconductor Material | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2011-04-14 | — | — | US | disclosed |
| EP-2248818-A1 | ORGANIC SEMICONDUCTOR MATERIAL | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC | 2009-02-19 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1999098-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-0319986-B1 | Anti-plasmin depressant | NIPPON SHINYAKU CO LTD (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5292750-A | piperidine compounds | NIPPON SHINYAKU CO. LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| US-5192772-A | Administering moranoline derivatives; anticoagulants | NIPPON SHINYAKU CO. LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
| EP-0319986-A2 | Fibrinolytic agents | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1989-06-14 | — | — | EP | disclosed |
| US-4576753-A | MICROBIOCIDES, ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-18 | — | — | US | disclosed |
| US-4304718-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| US-4264498-A | REACTED WITH AN ACID, ITS ACID HALIDE, OR ANHYDRIDE IN THE PRESENCE OF BORON TRIHALIDE AND AN ORGANIC BASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-04-28 | — | — | US | disclosed |
| US-4181800-A | ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | PPARD, PPARG, PPARA | CHAT 2548/4885ALDH1A1 1075/4885CYP2A6 326/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | CHAT 3056/4885ALDH1A1 739/4885CYP2A6 2233/4885 |
| US-20110087034-A1 | Organic Semiconductor Material | OR10J3, TST, OR51E2 | CHAT 1928/4885ALDH1A1 137/4885CYP2A6 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.